RxSight, Inc. (RXST) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted several concerns: a larger GAAP net loss, increased operating expenses, and weak revenue guidance for 2025. Although gross margin is expected to improve, the company anticipates lower margins in the near term. The Q&A revealed uncertainties about competitive pressures and reimbursement changes, with management offering vague responses on key metrics. Despite some optimism around international expansion and premium IOL demand, the market's reaction is likely to be negative due to financial weaknesses and unclear guidance, especially given the company's small-cap status.
Key Financial Performance
Revenue $30.3 million, down 14% year-over-year from $35.3 million. The decline was attributed to a decrease in LDD sales and seasonally stronger performance in the prior quarter.
LAL Revenue $25.7 million, up 6% year-over-year. This increase was due to higher demand for LALs, which represented 85% of total revenue, up from 69% in the prior year.
LDD Revenue $3.2 million, down 69% year-over-year. The decline was due to a significant drop in LDD unit sales, which fell 68% year-over-year.
Gross Margin 79.9%, an increase of 844 basis points year-over-year from 71.4%. The improvement was driven by a higher mix of higher-margin LAL revenue and lower unit costs for both LAL and LDD.
SG&A Expenses $27.3 million, up 7% year-over-year from $25.6 million. The increase was primarily due to higher personnel costs, stock-based compensation, and marketing studies.
R&D Expenses $9.1 million, up 3% year-over-year from $8.8 million. The increase was attributed to higher overhead costs, partially offset by lower materials costs.
GAAP Net Loss $9.8 million, compared to a net loss of $6.3 million in the prior year. The larger loss was due to increased operating expenses and stock-based compensation.
Non-GAAP Net Loss $1.7 million, compared to a net gain of $200,000 in the prior year. The shift to a loss was primarily due to higher operating expenses.
Cash Equivalents and Short-term Investments $227.5 million, unchanged from the previous quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of new programs: Introduced MasterClass and Elevate programs to optimize LAL workflow, enhance clinical confidence, and accelerate expertise in postoperative adjustability.
U.S. market progress: Aligned clinical and sales teams to improve customer engagement and training, driving growth in LAL and LDD adoption.
International expansion: Steady progress in Asia and Europe with regulatory and commercial initiatives; added an Executive VP of International to lead expansion.
Revenue performance: Q3 revenue of $30.3M, down 14% YoY; LAL revenue up 6% YoY to $25.7M, representing 85% of total revenue.
Gross margin improvement: Gross margin increased to 79.9%, driven by higher LAL mix and lower unit costs.
Operating expenses: SG&A expenses increased 7% YoY to $27.3M; R&D expenses rose 3% YoY to $9.1M.
Strategic focus on LAL: Positioning LAL as a premium IOL option amid declining Medicare fees for cataract surgery; focus on improving patient outcomes and practice economics.
Guidance update: Narrowed full-year revenue guidance to $125M-$130M; increased gross margin guidance to 76%-77%.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Third quarter revenue decreased by 14% compared to the same quarter last year and 10% compared to the previous quarter, indicating challenges in maintaining consistent revenue growth.
LDD Sales Decline: Sales of Light Delivery Devices (LDDs) dropped significantly by 68% year-over-year and 38% sequentially, reflecting potential issues in market demand or sales strategy.
Net Loss Increase: The company reported a GAAP net loss of $9.8 million in Q3 2025, a significant increase from the $6.3 million loss in Q3 2024, highlighting financial challenges.
Operating Expense Growth: Operating expenses are projected to increase by 7% to 14% year-over-year, driven by factors such as marketing, trade shows, and stock-based compensation, which could strain profitability.
Medicare Fee Reduction: Medicare's 2026 physician fee for cataract surgery is expected to decline by 11%, potentially impacting the adoption of premium IOL options like the Light Adjustable Lens.
International Expansion Risks: The company is in the early stages of international expansion, which involves regulatory and commercial challenges that could delay or limit growth in new markets.
R&D Cost Management: R&D expenses increased by 3% year-over-year, reflecting higher overhead costs, which could pressure margins if not managed effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2025 Revenue Guidance: Narrowed to $125 million to $130 million from the prior range of $120 million to $130 million, implying a year-over-year decline of 11% to 7%.
Q4 2025 Revenue Guidance: Expected to range between $23 million to $28 million, with flat to slightly higher LAL procedures sequentially at the top end of the range.
Gross Margin Guidance for 2025: Increased to 76% to 77% from the previous guidance of 72% to 74%, driven by a higher LAL mix and strategic approach to capital sales.
Operating Expenses for 2025: Expected to remain in the range of $145 million to $155 million, representing an implied increase of 7% to 14% over 2024. Sequential increase in Q4 expected due to trade show expenses, marketing, international hiring, and stock-based compensation.
Stock-Based Compensation Expense for 2025: Estimated to be between $30 million and $32 million, revised upward from the previous estimate of $27 million to $30 million.
International Expansion: Progressing in key markets in Asia and Europe, with efforts expected to contribute meaningfully over time as procedural volumes grow and local clinical experience deepens.
Market Trends: Medicare's 2026 physician fee for cataract surgery is declining 11%, expected to drive practices toward premium IOL options like the Light Adjustable Lens (LAL).
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What metrics are being used to evaluate the changes being implemented?
A:The key metric is the number of LAL procedures, which is considered an absolute number. Additionally, the number of physicians implanting each quarter and the number of LALs per LDD are also monitored.
Q:How is the company addressing new entrants in the market and the impact of reimbursement rate changes for 2026?
A:The company anticipates that lowered reimbursement for traditional cataract surgery will be a tailwind for premium IOLs. While new entrants may create some competitive trialing, the overall long-term impact is expected to be modest. The company is focusing on increasing total LAL procedures and helping its 1,100 customers grow their practices.
Q:What is driving the increase in active surgeons and how is the sales force realignment contributing?
A:The number of active surgeons has increased to between 1.7 and 2 per LDD. Surgeons are coming from new LDD sales, existing practices, and open-access centers. The sales force realignment is focused on increasing LAL volumes in existing practices and strategically adding new customers.
Q:What guidance is provided for LAL volumes and LDD placements in the fourth quarter and 2026?
A:The company expects sequential growth in LAL volumes in 2026, with a focus on increasing LAL procedures in existing accounts. LDD placements are expected to be lower in the fourth quarter, but this is part of a strategic shift to optimize the installed base rather than focusing solely on new LDD sales.
Q:What is the outlook for gross margins going forward?
A:The company expects gross margins to remain in the high 70% range, depending on the mix of LAL and LDD sales. The guided range is 77% to 78%, with LALs making up a significant portion of revenue.
Q:What is the timeline and contribution expected from international markets?
A:The company is making progress in regulatory access in Europe and Asia and is beginning to introduce the product beyond Canada. The international launch is expected to follow a similar course to the U.S., focusing on establishing KOL relationships and building clinical value.
Q:How is the health of the IOL market and consumer demand characterized?
A:The monofocal consumer is more affected by economic headwinds, while the premium market, where the company operates, is less impacted. Demand in the premium segment is expected to remain strong.
Q:What is the opportunity for LALs in post-refractive and LASIK patients?
A:Post-refractive patients represent about 5% of the overall cataract population but could be 10-20% in the company's customer profile. This segment is a natural starting point for doctors and represents a significant opportunity.
Q:What is the company's conviction about LALs becoming the standard of care in premium IOLs?
A:The company has achieved standard of care in some practices and remains confident in the potential for broader adoption. The focus is on increasing efficiency and confidence among users to expand utilization.
Q:How will reimbursement changes in 2026 impact LAL adoption?
A:Lower reimbursement for cataract surgery is expected to drive the need for premium IOLs to maintain profitability for practices. The company views this as a continued trend that supports the adoption of premium IOLs.
Q:What is the runway for commercial changes and new practice development programs?
A:The company is in the early stages of leveraging its installed base of 1,100 LDDs. Efforts are focused on increasing efficiency and confidence among users through peer-to-peer education and other initiatives.
Q:What is the updated thinking on the U.S. surgeon TAM?
A:The total number of cataract surgeons is 9,000 to 10,000. The company initially targeted those performing a higher percentage of premium IOLs but now sees broader opportunities across all practices. The focus is on educating physicians and expanding access through various models.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to questions about specific numerical guidance for 2026, particularly regarding LDD placements and LAL volumes. They emphasized a strategic shift and holistic approach but did not provide detailed projections. Additionally, the response to the impact of reimbursement changes on LAL adoption lacked specific quantification, relying on general trends and analogies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AAO trade
Adjustable Lens
Europe infrastructure
Executive Vice
Instructions Mr
International expansion
LAL LDD
LAL period
LAL procedure
LAL workflow
LDD practice
LDDs field
LDDs surgeon
Lens number
Light Adjustable
MasterClass program
Mr Vice
Officer Dr
President International
RD decrease
Relations response
SGA marketing
access LAL
addition unit
adjustability ophthalmologist
decline
engagement
margin improvement
marketing study
outlook
point increase
sale team
today RxSight
trade show
RXST Transcript
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
Neutral7-7
RxSight, Inc. (RXST) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
RxSight, Inc. (RXST) Q1 2026 Earnings Call Transcript
Positive5-9
The earnings call summary and Q&A reflect strong financial performance, positive product development updates, and strategic market expansion. Despite some uncertainties and lack of specific guidance for 2027, the company's focus on technological innovation, international growth, and shareholder return plans are favorable. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction over the next two weeks.
RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary shows strong Q4 2025 financial performance with a 25% revenue increase and improved margins. Despite the explicit and implied risks, the positive financial results and improved guidance for gross margins and international expansion efforts outweigh concerns. The market cap indicates a moderate reaction, thus predicting a positive stock price movement between 2% to 8%.
RXST Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
